Trial Profile
Phase III study of SUN Y7017 (memantine hydrochloride) in patients with moderately severe to severe dementia of the Alzheimer's type
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jun 2016
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 09 Jun 2016 New trial record